# Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients

> **NCT00411645** · PHASE3 · COMPLETED · sponsor: **Shire** · enrollment: 681 (actual)

## Conditions studied

- Cytomegalovirus Infections

## Interventions

- **DRUG:** maribavir
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00411645
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12-13
- **Primary completion:** 2008-11-10
- **Final completion:** 2009-05-23
- **Target enrollment:** 681 (ACTUAL)
- **Last updated:** 2021-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00411645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00411645, "Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00411645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*